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    Major  histocompatibility  complex  (MHC)  genes  are  involved  in  various 
mechanisms of pathogenesis and immunoediting of hematological diseases. This 
study  aimed  to  investigate  the  association  between  HLA  -A,  -B  and  -DRB1 
alleles  with  hematological  diseases.  In  this  study,  we  performed  DNA-based 
HLA  typing  by  polymerase  chain  reaction  analysis  with  sequence-specific 
primers (PCR-SSP) to distinguish HLA-A, -B, and -DRB1 alleles. Eighty-two 
patients  with  hematological  diseases  (29  with  acute  lymphoblastic  leukemia 
(ALL),  19  with  acute  nonlymphoblastic  leukemia  (ANLL),  5  with  chronic 
myelogenous leukemia (CML), 2 with chronic lymphocytic leukemia (CLL), 9 
with myelodysplastic syndrome (MDS), 9 with lymphomas (M.Hodgkin (HL) 
and  non-Hodgkin  (NHL)),  7  with  aplastic  anemia  (AA)  and  2  with  multiple 
myeloma (MM)),  were included in the study and compared with 111 healthy 
blood donors, residents from Vojvodina, evaluating the strength of the observed 
associations by measuring the aetiologic and preventive fractions. Among the 
alleles significantly associated with hematological diseases, HLA-A*24 showed 
an aetiologic fraction higher than those  of  HLA-A*26 and A*25 (RR=1.027, 64                                                                                                                   GENETIKA, Vol. 45, No.1,63-74, 2013 
EF=1.233,  RR=1.047,  EF=1.141  and  RR=1.213,  EF=0.910).Negative 
association with significant preventive fraction was observed with HLA-B*18 
and  HLA-DRB1*11  alleles,  with  RR=0.400,  PF=0.179  and  RR=0.587, 
PF=0.176. Our results suggest that HLA-A*24, A*26 and A*25 as associated 
more frequently than other specificities with a hypothetical disease predisposing 
genes, may play a role in the pathogenesis of hematological diseases. 
Key  words:  Human  Leukocyte  Antigens;  hematological  diseases; 
association. 
 
INTRODUCTION 
The  major  histocompatibility  complex  (MHC)  encodes  the  synthesis  of  human  leukocyte 
antigens (HLA) which represents the polymorphic membrane glycoproteins found on the surface 
of almost all nucleated cells (HLA class I molecules) and cells mainly involved in the immune 
response (HLA class II molecules). The HLA molecules serve as markers for self during the 
thymic maturation of T-cells and these cells always recognize foreign antigenic peptides in the 
context of self HLA  molecules. The loss of HLA antigens by neoplastic cells is considered 
important for tumor growth and metastasis (NOWAK et al., 2009, LIPINS et al., 2001). Since tumor 
neoantigens on the surface of aberrant cells are recognized by T-cells only in the context of the 
HLA  “self”  antigens,  loss  of  the  HLA  antigens  may  allow  the  tumors  to  escape 
immunosurveillance. HLA system is a kind of genetic marker of human being, and the most 
complicated  human  genetic  polymorphic  system  with  hereditary  features  of  haplotype 
inheritance and allele polymorphism and linkage disequilibrium. It playes an important role in 
the event of antigen recognition and presentation, immune response and modulation, destroying 
foreign  antigen  targeted  cells.  The  alleles  of  the  HLA  system  control  a  variety  of  immune 
functions and influence the susceptibility to more than 40 diseases, many of which have an 
autoimmune component (LIN et al., 2003,  MACHULLA et al., 2001,  SAUNTHARARAJAH et al., 
2002). More diseases have been shown to be associated with alleles of the HLA region than with 
any other genetic region (MUNDHADA et al., 2004, SAVRAN OGUZ et al., 2003,  ZHANG et al., 
2006,  HARTY  et  al.,  2002).  Conventional  serological  and  cellular  typing  methods  permit 
identification of the HLA class I and II specificities. However, in many cases reliable assignment 
of class I and II alleles is impossible due to the small number or poor quality of T- or B-cells or 
reduced expression of HLA molecules on the cell surface. Genomic HLA typing, using various 
polymerase chain reaction (PCR)-based typing methods, is accurate for HLA association studies 
and more importantly, more biologically relevant polymorphism can be detected with DNA-
based  tissue  typing  than  with  serology.  The  aim  of  this  study  was  for  the first  time  in  the 
Vojvodina region to determine the frequencies of HLA-A, -B and -DRB1 alleles using genomic 
tissue-typing methods in order to assess HLA association in hematological diseases. 
 
MATERIALS AND METHODS 
Eighty two patients from Vojvodina (40 females, 42 males, with a median age of 38,5 
years) were included in study. An informed consent of the individuals participating in the study 
was  obtained  and  all  institutional  ethics  requirements  were  met.  They  were  divided  into 
subgroups according to the type of disease: 29 suffering from acute lymphoblastic leukemia 
(ALL), 19 suffering from acute nonlymphoblastic leukemia (ANLL), 5 suffering from chronic 
myelogenous  leukemia  (CML),  2  suffering  from  chronic  lymphocytic  leukemia  (CLL),  9 S.VOJVODIC et al: HLA ALLELES ASSOCIATED WITH  HEMATOLOGICAL DISEASES                             65 
suffering  from  myelodysplastic  syndrome  (MDS),  9  suffering  from  lymphomas  (M.Hodgkin 
(HL) and non-Hodgkin (NHL)), 7 suffering from aplastic anemia (AA) and 2 suffering from 
multiple myeloma (MM). Control group consisted of 111 healthy blood donors who resided in 
the  same  geographic  area.  Genomic  DNA  were  extracted  from  buffy  coat  using  standard 
proteinase K digestion method followed by spin-column-based method (QIAamp Blood Mini 
isolation kit, Qiagen) (GREENSPOON et al., 1998). Amplification was performed by Polymerase 
Chain  Reaction-Sequence  Specific  Primer  (PCR-SSP)  employing  Micro  SSP
TM  DNA  (One 
Lambda, Inc. Canoga Park, CA, USA) as well as INNO-TRAIN DiagnostikGmbH (HLA-REDY 
GENE, Lot: G954011, Kronberg/Taunus,Germany). Assay was performed for DNA typing of 
alleles  HLA-A,  -B  and  -DRB1/3/4/5  (ADIB  et  al.,  2004).  Pre-opromized  primers  for  the 
amplification of  HLA-A, -B and -DRB1 genes in reaction were distributed in wells of PCR plate 
for  later  addition  of  DNA  samples,  Taq  polymerase  (AXITAQ-DNA  Polymerase,  INNO-
TRAIN,  Kronberg/  Taunus,  Germany,  Lot:  GOT  120)  and  dNTP-buffer  mix.  After 
amplification, electrophoresis in agarose gel 2% was undertaken, at 180 volts, for approximately 
20 minutes. A pair of specific primers amplifying a conserved region of the Human β-globin 
gene,  which is present in all DNA samples, was used to verify the integrity of the PCR reactions 
performed  by  Micro  SSP
TM  DNA,One  Lambda  kits.  On  the  contrary,  gene  sequence  of  the 
human growth hormone, HGH, was used as a positive internal control of HLA-REDY GENE, 
INNO-TRAIN kits. 
All statistical analyses were performed with the software Microsoft Office Excel 2002 
for Windows.  Relative risk (RR) for  measuring strenght of association  with each allele was 
calculated by the method of Woolf (ARMITAGE et al.,2002), according to following formula:    
P x C
C x P RR
− +
− +
= ,where 
Ρ
+ = is the number of patients who have a given allele; 
C
- = is the number of healthy persons who do not have a given allele; 
Ρ
-= is the number of patients who do not have a given allele; 
C
+  = is the number of healthy persons who have a given allele.  
 
When RR was higher than 1, we calculated the aetiologic fraction, while for RR values less than 
1, we calculated the preventive fraction. The aetiologic fraction (EF) or population atrributable 
risk, that gives the proportion of disease, due to the HLA marker associated with disease, was 
calculated according to method of Green, using following formula: 
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where FAD is the frequency of given HLA allele in the subgroup of patients and FAP is the 
frequency of HLA allele in controls. The preventive fraction (PF), that gives  the percentage of 
cases  that  can  be  prevented  if  a  population  is  exposed  to  an  intervention,  compared  to  an 
unexposed  population,  was  calculated  according  to  following  formula: 
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where RR is relative risk and f is the frequency of HLA allele in the subgroup of patients. The 
association was considered positive if the calculated EFs were higher than 0.15 and negative if 
calculated PFs were more than 0.15 (GREEN et al.,1982).  
 
 
RESULTS 
The allele frequencies of HLA-A, -B and -DRB1 gene in patients suffering from hematological 
disorders and healthy controls from population of Vojvodina were summarized in Tables 1a and 
1b. In total, 14 different HLA-A*, 23 different HLA-B* and 12 different HLA-DRB1* alleles 
were  found  in  investigated  groups  from  Vojvodina.  In  HLA-A  locus,  A*02  was  the  most 
frequent allele in both  of  groups  with  frequency  of  63%  in controls  and  57.3% in patients, 
respectively. In locus B, the most frequent alleles in controls were B*18, B*35 and B*51 with 
frequency of 29.7%, 28.8% and 27%, while in patients B*35 ranked as the first one with the 
frequency of 23.1% followed by B*44 (17%), B*51 (15.8%), B*07 and B*18 (14.6%). In locus 
DRB1, DRB1*11 ranked as the first one with the frequency of 42.3% in controls and 30.4% in 
patients, followed by DRB1*16 and DRB1*03 in controls (with frequency of 24.3% and 22.5%), 
and DRB1*13 (25.6%) and DRB1*15 (23.1%) in patients. 
 
 
Table  1a. Allelic frequencies of HLA-A and -DRB1 genes in patiens suffering from hematological 
disorders and controls from Vojvodina  
 
 
The results showing relative risk, aetiologic and preventive fraction are presented in Tables  2a 
and 2b. Our results pointed to the several HLA-A* alleles associated with an increased risk of 
developing  hematologic  diseases,  such  as:  A*24  (RR=1.027,  EF=1.233),  A*26  (RR=1.047, 
EF=1.141), respectively as well as A*25 (RR=1.106, EF=0.910), while A*30, A*31 and A*32 
Allele  Patients  Controls  Allele  Patients  Controls 
A*01  0.219  0.315  DRB1*01  0.219  0.198 
A*02  0.573  0.630  DRB1*03  0.195  0.225 
A*03  0.134  0.216  DRB1*04  0.121  0.126 
A*11  0.197  0.135  DRB1*07  0.207  0.135 
A*23  0.048  0.063  DRB1*08  0.048  0.054 
A*24  0.195  0.189  DRB1*09  0  0.018 
A*25  0.097  0.081  DRB1*10  0.024  0.018 
A*26  0.085  0.081  DRB1*11  0.304  0.423 
A*29  0  0.036  DRB1*12  0.048  0.045 
A*30  0.036  0.027  DRB1*13  0.256  0.171 
A*31  0.060  0.027  DRB1*14  0.060  0.063 
A*32  0.073  0.054  DRB1*15  0.231  0.189 
A*33  0.048  0.054  DRB1*16  0.170  0.243 
A*34  0.012  0       
   A*68  0.060  0.072       
   A*69  0.024  0       S.VOJVODIC et al: HLA ALLELES ASSOCIATED WITH  HEMATOLOGICAL DISEASES                             67 
showed  RR  higher  than  1  (RR=1.354,  RR=2.316,  RR=1.368,  respectively),  but  without 
significant  association  (EF=0.009,  EF=0.033,  EF=0.020).  Our  results  showed  significantly 
decreased frequency  of  B*18 allele (RR=0.400, PF=0.179) and DRB1*11 allele (RR=0.587, 
PF=0.176)  in  the  group  of  patients  compared  to  controls,  which  indicates  to  their  possible 
protective role from the risk of investigated hematological disorders. The discrepancy of relative 
risk higher than 1 and nonsignificant association was especially observed for HLA-B*50 and 
B*55 alleles where RR=4.139 and 4.263, while EF were 0.027 and 0.056, respectively. 
The  distribution  of  HLA-A,  -B  and  -DRB1  alleles  in  investigated  subgroups  of  patients  is 
presented in Tables 3a and 3b, showing the influence of particular subgroups allele frequencies 
on total frequencies, relative risk and strength of association. 
 
 
Table    1b.  Allelic frequencies  of  HLA-B  genes  in  patiens suffering  from  hematological  disorders and 
controls from Vojvodina  
Allele  Patients  Controls 
B*07  0.146  0.072 
B*08  0.121  0.180 
B*13  0.109  0.063 
B*14  0.085  0.054 
B*15  0.048  0.081 
B*18  0.146  0.297 
B*27  0.109  0.054 
B*35  0.231  0.288 
B*37  0.012  0.045 
B*38  0.097  0.054 
B*39  0.048  0.027 
B*40  0.085  0.072 
B*41  0.024  0.036 
B*44  0.170  0.216 
B*45  0  0.009 
B*48  0.012  0 
B*49  0.024  0.018 
B*50  0.036  0.009 
B*51  0.158  0.270 
B*52  0.048  0.054 
B*53  0.012  0 
B*55  0.073  0.018 
B*56  0.036  0.027 
B*57  0.036  0.054 
B*58  0  0.009 
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Table  2a. Relative risk, aetiologic and preventive fractions in investigated groups from Vojvodina for 
HLA-A and -DRB1 alleles 
 
 
DISCUSSION 
This is the first PCR-based HLA association study in hematological disorders, which analyzed 
healthy controls as well as patient from a single center using the same technique. Previously 
reported associations of HLA class I and class II antigens and leukemias reported for region of 
Vojvodina, were obtained by serological HLA typing. Our results pointed to the importance of 
HLA DNA typing for the investigation of HLA disease associations, since  in contrast to the 
results of serologic typing, several differences in HLA frequencies between patients and controls 
were revealed by PCR-based DNA typing. These differences focused mainly on the MHC class 
II region (VOJVODI  et al., 2001, VOJVODI , 2008, VOJVODI  and ADEMOVI -SAZDANI , 2011a, 
VOJVODI  and  ADEMOVI -SAZDANI , 2011b,  VOJVODI  and  ADEMOVI -SAZDANI , 2012). Our 
study showed that the relative risk to develop hematological disease was obtained in a patients 
having several HLA alleles such as HLA-B*55, -B*50, -B*07, -B*27, -DRB1*07, -DRB1*13, -
DRB1*15, -B*38, -B*14, -A*31 and other, but significant association with EF > 0.15   was 
observed only for alleles HLA-A*24, -A*25 and  -A*26. Analogically, the decreased frequencies 
in patients than in controls were obtained for many of HLA alleles but the  remarkable results 
with PF > 0.15 were only observed for HLA-B*18 and -DRB1*11 alleles. Analysis of impact of 
investigated diseases HLA allele frequencies to increased total frequency for HLA-A*24 allele 
shows that allele frequencies are highest in patients suffering from chronic leukemias and ANLL 
(0.285 and 0.210). On a contrary, the greatest impact on increased frequency of HLA-A*25 
allele showed a high frequency in AML patients (0.210) and bone marrow failure syndromes 
such as MDS and AA with frequency of 0.187. The different situation is observed with HLA-
A*26 total frequency, where the greatest impact on it is manifested for the frequency in patients 
suffering from ALL (0.172). This results suggest that the HLA-A*24 allele could be the possible 
Allele  RR  EF  PF  Allele  RR  EF  PF 
A*01  0.602  -  0.126  DRB1*01  1.125  0.026  - 
A*02  0.767  -  0.148  DRB1*03  0.824  -  0.040 
A*03  0.563  -  0.094  DRB1*04  0.952  -  0.006 
A*11  0.684  -  0.042  DRB1*07  1.656  0.083  - 
A*23  0.754  -  0.015  DRB1*08  0.888  -  0.006 
A*24  1.027  1.233*  -  DRB1*09  -  -  - 
A*25  1.213  0.910*  -  DRB1*10  1.350  0.006  - 
A*26  1.047  1.141*  -  DRB1*11  0.587  -  0.176* 
A*29  -  -  -  DRB1*12  1.076  0.003  - 
A*30  1.354  0.009  -  DRB1*13  1.622  0.102  - 
A*31  2.316  0.033  -  DRB1*14  0.955  -  0.002 
A*32  1.368  0.020  -  DRB1*15  1.298  0.051  - 
A*33  0.888  -  0.006  DRB1*16  0.632  -  0.089 
A*34  -  -  -         
A*68  0.841  -  0.010         
A*69  -  -  -         S.VOJVODIC et al: HLA ALLELES ASSOCIATED WITH  HEMATOLOGICAL DISEASES                             69 
risk marker for developing chronic leukemias and ANLL, HLA-A*25 could be the possible risk 
marker for developing AML and MDS/AA while HLA-A*26 allele is susceptibility factor for 
ALL. The results of this study  are in accordance with several reports that suggest that a genetic 
factors located  within  or close to the HLA  gene loci confers susceptibility  to hematological 
diseases (SHICHISHIMA et al., 2006,  STARATSCHEK-JOX et al.,2002, DORAK et al., 1999, LECH-
MARANDA, et al., 2007, NOWAK et al., 2009). The limitation of this study is related to inability 
for displaying the HLA-A, -B and -DRB1 allele frequencies separately for each subgroup of 
disease as it would be unrealistic and unsuitable for statistical analysis due to the small number 
of subjects in individual groups. Despite that, the importance of this study is in the fact that the 
data processed by using molecular typing method are shown for  the first time in a single center 
and for the studied region. 
 
 
Table  2b. Relative risk, aetiologic and preventive fractions in investigated groups from Vojvodina for HLA-
B alleles 
Allele  RR  EF  PF 
B*07  2.185  0.079  - 
B*08  0.625  -  0.067 
B*13  1.269  0.049  - 
B*14  1.617  0.032  - 
B*15  0.575  -  0.034 
B*18  0.400  -  0.179* 
B*27  2.136  0.058  - 
B*35  0.735  -  0.076 
B*37  0.259  -  0.033 
B*38  1.873  0.045  - 
B*39  1.829  0.021  - 
B*40  1.190  0.014  - 
B*41  0.662  -  0.012 
B*44  0.737  -  0.057 
B*45  -  -  - 
B*48  -  -  - 
B*49  1.350  0.006  - 
B*50  4.139  0.027  - 
B*51  0.502  -  0.135 
B*52  0.888  -  0.006 
B*53  -  -  - 
B*55  4.263  0.056  - 
B*56  1.354  0.009  - 
B*57  0.658  -  0.018 
B*58  -  -  - 
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Table  3a. The distribution of HLA-A and -DRB1 alleles in nvestigated subgroups of patients 
 
Allele  ALL    n=29  AML  n=19  CLL/CML  
n=7 
HL/NHL/MM 
n=11 
AA/MDS 
n=16 
A*01  0.137  0.210  0  0.454  0.312 
A*02  0.551  0.631  0.571  0.545  0.565 
A*03  0.172  0.210  0.142  0.090  0.062 
A*11  0.068  0.052  0.285  0  0.187 
A*23  0.103  0  0  0  0.062 
A*24  0.206  0.210  0.285  0.181  0.125 
A*25  0.034  0.210  0  0  0.187 
A*26  0.172  0.052  0.142  0  0 
A*29  0  0  0  0  0 
A*30  0  0  0  0.181  0.062 
A*31  0.103  0.105  0  0  0 
A*32  0.103  0.157  0  0  0 
A*33  0.034  0  0  0.181  0.062 
A*34  0  0  0  0.090  0 
A*68  0.137  0.052  0  0  0 
A*69  0  0  0.142  0.090  0 
DRB1*01  0.206  0.210  0.428  0.181  0.187 
DRB1*03  0.206  0.157  0.142  0.272  0.187 
DRB1*04  0.172  0.105  0.142  0.090  0.062 
DRB1*07  0.275  0.157  0.428  0.090  0.125 
DRB1*08  0.034  0.105  0  0  0.062 
DRB1*09  0  0  0  0  0 
DRB1*10  0.034  0  0  0.090  0 
DRB1*11  0.137  0.315  0.142  0.636  0.437 
DRB1*12  0.034  0  0.142  0  0.125 
DRB1*13  0.344  0.157  0.142  0.272  0.250 
DRB1*14  0.068  0.052  0  0  0.125 
DRB1*15  0.275  0.315  0.142  0.090  0.187 
DRB1*16  0.137  0.263  0.285  0.090  0.125 
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Table  3b. The distribution of HLA-B alleles in nvestigated subgroups of patients 
 
Allele  ALL    n=29  AML  n=19  CLL/CML  
n=7 
HL/NHL/MM 
n=11 
AA/MDS 
n=16 
B*07  0.206  0.210  0.142  0  0.062 
B*08  0.068  0.210  0  0.090  0.187 
B*13  0.103  0.105  0.142  0.181  0.062 
B*14  0.068  0  0.142  0.181  0.125 
B*15  0.103  0  0  0  0.062 
B*18  0.137  0.105  0.285  0.090  0.187 
B*27  0.103  0.157  0.285  0  0.062 
B*35  0.172  0.315  0.142  0.454  0.125 
B*37  0  0  0  0.090  0 
B*38  0.137  0.052  0.142  0  0.125 
B*39  0.034  0.105  0.142  0  0 
B*40  0.034  0.210  0  0.181  0 
B*41  0.034  0  0  0.090  0 
B*44  0.206  0.105  0.142  0.090  0.250 
B*45  0  0  0  0  0 
B*48  0  0  0  0  0.062 
B*49  0  0  0  0.090  0.062 
B*50  0.103  0  0  0  0 
B*51  0.137  0.157  0.142  0.272  0.125 
B*52  0.068  0.052  0  0  0.062 
B*53  0.034  0  0  0  0 
B*55  0.034  0.105  0  0.090  0.125 
B*56  0.034  0  0.142  0  0.062 
B*57  0.034  0.052  0  0.090  0 
B*58  0  0  0  0  0 
 
CONCLUSION 
The results of the present study suggest that HLA-A*24, -A*25 and -A*26 are a genetic risk 
factors  for  hematological  diseases.  HLA-B*18  and  -DRB1*11  alleles  may  be  the  possible 
protective factor for developing investigated diseases. We hope that these results will be used as 
a  guide  for  further  functional  studies  and    that  they  would  have  diagnostic  and  prognostic 
implications. 
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Izvod 
Geni  glavnog  kompleksa  histokompatibilnosti  (MHC)  su  uklju eni  u  razli ite  mehanizme 
etiopatogeneze  i imunološkog  nadzora  hematoloških  bolesti.  Cilj  ove  studije  je  da  se  istraži 
udruženost HLA-A,-B i -DRB1 alela sa hematološkim bolestima. U ovoj studiji primenjena je 
molekulska  metoda  HLA  tipizacije  putem  lan ane  reakcije  polimeraze  sa  prajmerima 
specifi nim za sekvencu (PCR-SSP) za determinisanje HLA-A,-B i -DRB1 alela. Osamdeset-dva 
bolesnika sa hematološkim oboljenjima (29 sa akutnom limfoblastnom leukemijom (ALL), 19 sa 
akutnom  nelimfoblastnom  leukemijom  (ANLL),  5  sa  hroni nom  mijelogenom  leukemijom 
(CML), 2 sa hroni nom limfocitnom leukemijom (CLL), 9 sa mijelodisplasti nim sindromom 
(MDS), 9 sa limfomima (M.Hodgkin (HL) i Non-Hodgkin (NHL)), 7 sa aplasti nom anemijom 
(AA) i 2 sa multiplim mijelomom (MM)), su uklju eni u studiju. Kontrolna grupa od 111 zdravih 
dobrovoljnih davaoca krvi sa teritorije Vojvodine poslužila je za procenu stepena udruženosti 
merenjem  etiološke  i  preventivne  frakcije.  Me u  alelima  koji  su  zna ajno  udruženi  sa 
hematološkim  bolestima,  kod  HLA-A*24  alele  uo ena  je  viša  vrednost  etiološke  frakcije  u 
odnosu na one kod HLA-A*26 i A*25 alele (RR = 1.027, EF = 1.233, RR = 1.047, EF = 1.141 i 
RR = 1.213, EF = 0.910). Negativna asocijacija sa zna ajnom preventivnom frakcijom je uo ena 
za HLA-B*18 i HLA-DRB1*11 alele, sa RR = 0.400, PF = 0.179 i RR = 0.587, PF= 0.176. Naši 
rezultati sugerišu da su HLA-A*24, -A*26 i -A*25 alele  hipoteti ki predisponiraju i geni koji 
mogu imati ulogu u patogenezi hematoloških bolesti. 
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